HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development
The aim of this study was to develop an analytical method for selective determination of OATD-02 by high-performance liquid chromatography (HPLC) with post-column derivatization and fluorescence detection (FLD). OATD-02, a new boronic acid derivative, is a highly potent anticancer arginase inhibitor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/13/16/9201 |
| _version_ | 1797585622411509760 |
|---|---|
| author | Elzbieta Sobolewska Magdalena Tyszkiewicz Roman Blaszczyk Magdalena Biesaga |
| author_facet | Elzbieta Sobolewska Magdalena Tyszkiewicz Roman Blaszczyk Magdalena Biesaga |
| author_sort | Elzbieta Sobolewska |
| collection | DOAJ |
| description | The aim of this study was to develop an analytical method for selective determination of OATD-02 by high-performance liquid chromatography (HPLC) with post-column derivatization and fluorescence detection (FLD). OATD-02, a new boronic acid derivative, is a highly potent anticancer arginase inhibitor in clinical development. Chromatographic analysis of OATD-02 poses problems because this molecule has weak ultraviolet absorption. The derivatization reaction was based on the reaction between boronic acid from OATD-02 and alizarin solution. The optimized mobile phase consisted of a mixture of sodium bicarbonate in water and acetonitrile at a flow rate of 0.50 mL/min. Alizarin solution in methanol was delivered at a flow rate of 0.50 mL/min. The fluorescent complexes were detected by a fluorescence detector (excitation and emission wavelengths at 470 and 580 nm, respectively). The present method demonstrated proper values for selectivity, linearity, recovery (>99%), precision (RSD: 0.6%), sensitivity (LOD: 20 µg/mL and LOQ: 50 µg/mL), stability of solutions, and robustness. |
| first_indexed | 2024-03-11T00:09:41Z |
| format | Article |
| id | doaj.art-8ef73bdfc5c7465fa5218c3957cda005 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-11T00:09:41Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-8ef73bdfc5c7465fa5218c3957cda0052023-11-19T00:05:59ZengMDPI AGApplied Sciences2076-34172023-08-011316920110.3390/app13169201HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical DevelopmentElzbieta Sobolewska0Magdalena Tyszkiewicz1Roman Blaszczyk2Magdalena Biesaga3Faculty of Chemistry, University of Warsaw, Pasteur 1 Street, 02-093 Warsaw, PolandMolecure SA, Zwirki i Wigury 101 Street, 02-089 Warsaw, PolandMolecure SA, Zwirki i Wigury 101 Street, 02-089 Warsaw, PolandFaculty of Chemistry, University of Warsaw, Pasteur 1 Street, 02-093 Warsaw, PolandThe aim of this study was to develop an analytical method for selective determination of OATD-02 by high-performance liquid chromatography (HPLC) with post-column derivatization and fluorescence detection (FLD). OATD-02, a new boronic acid derivative, is a highly potent anticancer arginase inhibitor in clinical development. Chromatographic analysis of OATD-02 poses problems because this molecule has weak ultraviolet absorption. The derivatization reaction was based on the reaction between boronic acid from OATD-02 and alizarin solution. The optimized mobile phase consisted of a mixture of sodium bicarbonate in water and acetonitrile at a flow rate of 0.50 mL/min. Alizarin solution in methanol was delivered at a flow rate of 0.50 mL/min. The fluorescent complexes were detected by a fluorescence detector (excitation and emission wavelengths at 470 and 580 nm, respectively). The present method demonstrated proper values for selectivity, linearity, recovery (>99%), precision (RSD: 0.6%), sensitivity (LOD: 20 µg/mL and LOQ: 50 µg/mL), stability of solutions, and robustness.https://www.mdpi.com/2076-3417/13/16/9201post-column derivatizationactive pharmaceutical ingredientarginase inhibitorHPLC |
| spellingShingle | Elzbieta Sobolewska Magdalena Tyszkiewicz Roman Blaszczyk Magdalena Biesaga HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development Applied Sciences post-column derivatization active pharmaceutical ingredient arginase inhibitor HPLC |
| title | HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development |
| title_full | HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development |
| title_fullStr | HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development |
| title_full_unstemmed | HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development |
| title_short | HPLC with Post-Column Derivatization with Alizarin for Determination of OATD-02, an Anticancer Arginase Inhibitor in Clinical Development |
| title_sort | hplc with post column derivatization with alizarin for determination of oatd 02 an anticancer arginase inhibitor in clinical development |
| topic | post-column derivatization active pharmaceutical ingredient arginase inhibitor HPLC |
| url | https://www.mdpi.com/2076-3417/13/16/9201 |
| work_keys_str_mv | AT elzbietasobolewska hplcwithpostcolumnderivatizationwithalizarinfordeterminationofoatd02ananticancerarginaseinhibitorinclinicaldevelopment AT magdalenatyszkiewicz hplcwithpostcolumnderivatizationwithalizarinfordeterminationofoatd02ananticancerarginaseinhibitorinclinicaldevelopment AT romanblaszczyk hplcwithpostcolumnderivatizationwithalizarinfordeterminationofoatd02ananticancerarginaseinhibitorinclinicaldevelopment AT magdalenabiesaga hplcwithpostcolumnderivatizationwithalizarinfordeterminationofoatd02ananticancerarginaseinhibitorinclinicaldevelopment |